Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 854 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ November 24, 2018 ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under... November 17, 2025 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... November 22, 2024 Load more HOT NEWS 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... Activity and Safety of Atezolizumab Combined with Carboplatin and Pemetrexed in...
